<scp>ILAE</scp> classification of the epilepsies: Position paper of the <scp>ILAE</scp> Commission for Classification and Terminology
Pourquoi ce travail est-il dans la base ?
Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.
Résumé
The International League Against Epilepsy (ILAE) Classification of the Epilepsies has been updated to reflect our gain in understanding of the epilepsies and their underlying mechanisms following the major scientific advances that have taken place since the last ratified classification in 1989. As a critical tool for the practicing clinician, epilepsy classification must be relevant and dynamic to changes in thinking, yet robust and translatable to all areas of the globe. Its primary purpose is for diagnosis of patients, but it is also critical for epilepsy research, development of antiepileptic therapies, and communication around the world. The new classification originates from a draft document submitted for public comments in 2013, which was revised to incorporate extensive feedback from the international epilepsy community over several rounds of consultation. It presents three levels, starting with seizure type, where it assumes that the patient is having epileptic seizures as defined by the new 2017 ILAE Seizure Classification. After diagnosis of the seizure type, the next step is diagnosis of epilepsy type, including focal epilepsy, generalized epilepsy, combined generalized, and focal epilepsy, and also an unknown epilepsy group. The third level is that of epilepsy syndrome, where a specific syndromic diagnosis can be made. The new classification incorporates etiology along each stage, emphasizing the need to consider etiology at each step of diagnosis, as it often carries significant treatment implications. Etiology is broken into six subgroups, selected because of their potential therapeutic consequences. New terminology is introduced such as developmental and epileptic encephalopathy. The term benign is replaced by the terms self-limited and pharmacoresponsive, to be used where appropriate. It is hoped that this new framework will assist in improving epilepsy care and research in the 21st century.
Récupéré en direct depuis OpenAlex et désinversé. Les résumés ne sont pas conservés dans cette base de données : les index inversés représentent 8,6 Go des 9,3 Go de texte de la base, et le serveur dispose de 13 Go libres.
La notice
- Revue
- Epilepsia
- Thématique
- Epilepsy research and treatment
- Domaine
- Medicine
- Établissements canadiens
- University of CalgaryBC Children's HospitalUniversity of British Columbia
- Organismes subventionnaires
- CilagUCB PharmaNational Health and Medical Research CouncilMedical Research CouncilCanadian Institutes of Health ResearchUniversity of California, Los AngelesSun PharmaUniversidade Católica de BrasíliaFundação BialEisaiEpilepsy Research UKNeuroPaceNational Institutes of HealthMylanSupernus PharmaceuticalsZynerba PharmaceuticalsUpsher-SmithDivision of Arctic SciencesSage TherapeuticsEpilepsiatutkimussäätiöDravet Syndrome UKZogenixAlva FoundationLundbeckfondenU.S. Department of DefenseYorkhill Children’s CharityGW PharmaceuticalsSanofiCitizens United for Research in EpilepsyNovartisAcorda TherapeuticsStockholms Läns LandstingTakeda Pharmaceuticals U.S.A.PfizerHumanities Research Center, Rice UniversityUltragenyx PharmaceuticalGlaxoSmithKlineVertex PharmaceuticalsMarch of Dimes FoundationNational Institute of Neurological Disorders and StrokeCURE Childhood CancerH. Lundbeck A/SSunovion
- Mots-clés
- EpilepsyTerminologyEtiologyMedicineEpilepsy syndromesGeneralized epilepsyPediatricsIntensive care medicinePsychiatry
- Résumé présent dans OpenAlex
- oui